Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 5.59

From 52W high−59.49%

Volume200.00

Market capHKD 1.35B

P/E (TTM)—

P/S (TTM)—

Div yield1.17%

Key dataSep 18, 2026

Open

HKD 5.59

From 52W high

−59.49%

Volume

200.00

Market cap

HKD 1.35B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

59.6

MomentumView details →

1D Return

−0.09%

YTD Return

−26.06%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−0.09%

YTD Return

−26.06%

1Y Return

−53.42%

RSI (14)

59.6

vs 50D SMA

+2.78%

vs 200D SMA

−21.09%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

1.17%

Div Rate

HKD 0.07

Div Growth 1Y

+7.44%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

Jiyuan Gene announced that its board resolved to continue its H-share buyback plan, repurchasing up to 100 million RMB of H-shares on the open market with its own funds before the buyback mandate expires.32d ago

Jiuyuan Gene announced its interim results for the six months ended June 2026, with revenue of RMB 631 million, down 1.2% year-on-year, and net profit of RMB 91.269 million, up 1.2% year-on-year.32d ago

Similar companies

Zhaoke Ophthalmology Limited06622.HK LB Pharmaceuticals Inc Common StockLBRX ORIC Pharmaceuticals, Inc.ORIC First Tracks Biotherapeutics IncTRAX Damora Therapeutics, Inc.DMRA ImmuneOnco Biopharmaceuticals (Shanghai) Inc.01541.HK Find similar companies →

Latest newsMore news →

Jiyuan Gene announced that its board resolved to continue its H-share buyback plan, repurchasing up to 100 million RMB of H-shares on the open market with its own funds before the buyback mandate expires.32d ago Jiuyuan Gene announced its interim results for the six months ended June 2026, with revenue of RMB 631 million, down 1.2% year-on-year, and net profit of RMB 91.269 million, up 1.2% year-on-year.32d ago